Safeguarding Women from Chemical Abortion Act

S.4066, titled the Safeguarding Women from Chemical Abortion Act, was introduced in the Senate on March 11, 2026, by Senator Hawley (R-MO) and has six cosponsors. It was subsequently referred to the Committee on Health, Education, Labor, and Pensions. The bill's primary objective is to deem the FDA's approved application for mifepristone (marketed as Mifeprex, also known as RU-486) for the termination of intrauterine pregnancy as withdrawn. It also seeks to establish a federal tort for harm to women caused by chemical abortion drugs. This bill does not authorize or appropriate any specific funding. Instead, its mechanism is regulatory, aiming to remove a specific drug from the market and create legal liability. The direct impact would be on pharmaceutical companies that manufacture or distribute mifepristone. As the bill seeks to withdraw FDA approval, it would effectively halt the legal sale and distribution of the drug for its indicated use, leading to a loss of revenue for any companies involved. There are no publicly traded pure-play companies solely focused on mifepristone production, and the manufacturers are typically larger, diversified pharmaceutical firms where this product represents a small fraction of overall revenue, thus no specific tickers are identified as primary beneficiaries or losers. Structurally, the bill creates a significant headwind for any pharmaceutical company with products in the reproductive health space, particularly those related to abortion. While no direct funding is involved, the regulatory changes would alter the market landscape for these products. The bill is currently in the early stages of the legislative process, having only been introduced and referred to committee. It has a companion bill, H.R.7902, in the House of Representatives, which indicates a coordinated legislative effort. For S.4066 to advance, it must be considered and passed by the Senate Committee on Health, Education, Labor, and Pensions, then by the full Senate, and subsequently reconciled with its House companion before being sent to the President for signature. The recent Presidential Executive Order on Accelerating Medical Treatments for Serious Mental Illness, dated April 18, 2026, is not directly relevant to S.4066. The Executive Order focuses on psychedelic-based therapies for mental health and does not intersect with the regulatory framework or market for reproductive health drugs like mifepristone. Therefore, it neither amplifies nor conflicts with the legislative activity of S.4066.